Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cholecalciferol × Dermatologic × Clear all

Phase

Status

Completed 4 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Gastrointestinal 3 Classical hematology 2 Breast 2 Other neoplasm 1 Other 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 46 Cyclophosphamide 45 Ipilimumab 40 Nivolumab 36 aldesleukin 29 Interleukin-2 21 fludarabine 19 Vemurafenib 18 fludarabine phosphate 17 Radiotherapy 15 dabrafenib 14 Temozolomide 13 trametinib 12 Radiosurgery 10 spartalizumab 8 cobimetinib 8 Filgrastim 8 Dacarbazine 8 Biopsy 8 poly ICLC 7 binimetinib 7 Introns 7 CTLA-4 Antigen 7 Antilymphocyte Serum 7 encorafenib 6 Cyclosporine 6 tanespimycin 5 montanide ISA 51 5 avelumab 5 atezolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01264874 2018-01-31

MelaViD

European Institute of Oncology

Phase 3 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡